Flag of the European Union EU Clinical Trials Register Help

Clinical trials for cannabidiol

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    89 result(s) found for: cannabidiol. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2019-003591-40 Sponsor Protocol Number: 131082019 Start Date*: 2020-06-16
    Sponsor Name:Medizinische Universität Wien, Universitätsklinik für Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie
    Full Title: Efficacy of Cannabidiol in Treatment of Pain due to symptomatic Osteoarthritis of the Knee: A randomized, double-blind, placebo-controlled
    Medical condition: Painful osteoarthritis of the knee
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2013-000361-36 Sponsor Protocol Number: 12/0278 Start Date*: 2013-11-12
    Sponsor Name:Joint Research Office
    Full Title: A phase IIa/b, randomised, double-blind, placebo-controlled, single-site, parallel group clinical trial to examine cannabidiol (CBD) as a pharmacological treatment for cannabis dependence in a youn...
    Medical condition: 'Moderate cannabis use disorder' as defined by the diagnostic criteria in DSM-5 (published in May 2013), similar to the previous term 'cannabis dependence' (DSM-4).
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004873 10007177 Cannabis dependence LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-005198-38 Sponsor Protocol Number: CANNA1 Start Date*: 2018-10-26
    Sponsor Name:Odense University Hospital
    Full Title: Tetra-hydro-cannabinol, cannabidiol and their combination for the treatment of peripheral neuropathic pain. A randomised placebo-controlled trial.
    Medical condition: Peripheral neuropathic pain due to polyneuropathy, postherpetic neuralgia, or peripheral nerve injury (surgical or traumatic).
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10077974 Peripheral neuropathic pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2012-004335-23 Sponsor Protocol Number: CBD-FEP Start Date*: 2013-12-30
    Sponsor Name:Central Institute of Mental Health
    Full Title: A four-week, multicentre, double-blinded, randomised, active- and placebo-controlled, parallel-group trial investigating efficacy and safety of cannabidiol in acute, early-stage schizophrenic patie...
    Medical condition: Acute early-stage psychosis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10022891 - Investigations 10022891 Investigations SOC
    17.0 10018065 - General disorders and administration site conditions 10018065 General disorders and administration site conditions SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Temporarily Halted) DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-000240-26 Sponsor Protocol Number: CBD_ADD_IN Start Date*: 2013-10-29
    Sponsor Name:King's College London [...]
    1. King's College London
    2. South London and Maudsley NHS Foundation Trust
    Full Title: Cannabidiol as an add-on therapy in treatment-refractory psychotic disorders
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    16.1 10037175 - Psychiatric disorders 10039628 Schizophrenia and other psychotic disorders HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-003529-41 Sponsor Protocol Number: ABR58805 Start Date*: 2017-02-22
    Sponsor Name:University Medical Center Utrecht
    Full Title: CANGLIA: Endocannabinoid control of microglia activation as a new therapeutic target in the treatment of schizophrenia
    Medical condition: Schizophrenia patients
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2020-003739-62 Sponsor Protocol Number: 2021-74835 Start Date*: 2021-06-23
    Sponsor Name:University Medical Center Utrecht
    Full Title: BOOSTCAMP: Boosting the endocannabinoid system before the treatment of anxiety symptoms
    Medical condition: PTSD and anxiety disorders
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-004094-17 Sponsor Protocol Number: 40-41200-98-9269 Start Date*: 2015-11-03
    Sponsor Name:Universiteit Utrecht
    Full Title: Cannabidiol enhancement of exposure therapy in treatment refractory patients with phobias.
    Medical condition: Phobic anxiety disorders: either generalized social phobia or panic disorder with agoraphobia.
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004873 10068299 Fear symptoms and phobic disorders (incl social phobia) HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: View results
    EudraCT Number: 2020-004294-48 Sponsor Protocol Number: 20200106 Start Date*: 2021-07-07
    Sponsor Name:Amsterdam UMC, location VUmc
    Full Title: Glioma: Reducing Anxiety by conSuming cannabinoidS – GRASS study. Treating anxiety with CBD in glioma patients – A randomized-controlled trial
    Medical condition: Primary brain tumor patients with anxiety symptoms
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-002315-98 Sponsor Protocol Number: MedicalcannabisMSSCI2018 Start Date*: 2018-12-06
    Sponsor Name:Aarhus Universitetshospital
    Full Title: The effect of medical cannabis on neuropathic pain and spasticity in patients with Multiple Sclerosis and in patients with spinal cord injury. A multicenter national placebo-controlled trial
    Medical condition: Central neuropathic pain and spasticity
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10028335 Muscle spasticity PT
    20.0 10029205 - Nervous system disorders 10077975 Central neuropathic pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2014-002942-33 Sponsor Protocol Number: GWEP1428 Start Date*: 2015-10-27
    Sponsor Name:GW Research Ltd
    Full Title: A phase 2, double-blind, randomized, placebo-controlled study to investigate possible drug-drug interactions between clobazam and cannabidiol (GWP42003-P)
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    18.1 10010331 - Congenital, familial and genetic disorders 10073677 Severe myoclonic epilepsy of infancy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-004169-18 Sponsor Protocol Number: Sat-CIEN-02 Start Date*: 2017-02-22
    Sponsor Name:Centro de Investigación Biomédica en Red, Enfermedades Neurodegenerativas (CIBERNED)
    Full Title: A multicenter, randomized, double-blind, placebo-controlled, 4-arm, 26 week parallel-group study to evaluate the safety, tolerability and anti-inflammatory effect of three oromucosal doses of Sativ...
    Medical condition: Patients with mild cognitive impairment of Alzheimer type or early Alzheimer dementia.
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10074616 Prodromal Alzheimer's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-002819-21 Sponsor Protocol Number: GWND19189 Start Date*: Information not available in EudraCT
    Sponsor Name:GW Research Ltd
    Full Title: An exploratory, Phase 2, randomized, double-blind, placebo-controlled trial to investigate the safety and efficacy of cannabidiol oral solution (GWP42003-P; CBD-OS) in children and adolescents with...
    Medical condition: Autism Spectrum Disorder (ASD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10063844 Autism spectrum disorder PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2019-003623-37 Sponsor Protocol Number: CAN-PDP Start Date*: 2020-02-12
    Sponsor Name:King's College London [...]
    1. King's College London
    2. South London and Maudsley NHS Foundation Trust
    Full Title: CANnabidiol for Parkinson’s Disease Psychosis
    Medical condition: Parkinson's disease psychosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10074835 Parkinson's disease psychosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2019-002106-52 Sponsor Protocol Number: CANBiS-AD Start Date*: 2020-03-19
    Sponsor Name:King's College London [...]
    1. King's College London
    2. South London and Maudsley NHS Foundation Trust
    Full Title: CANnabidiol for Behavioural Symptoms in Alzheimer’s Disease
    Medical condition: Alzheimer's disease patients with BPSD
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2018-004893-84 Sponsor Protocol Number: CBD-P Start Date*: 2019-08-22
    Sponsor Name:Mental Health Center Glostrup
    Full Title: Cannabidiol for treatment of non-affective psychosis and cannabis use
    Medical condition: Non-affective psychosis and lifetime cannabis use
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10037234 Psychosis LLT
    21.1 100000004869 10070996 Cannabis use LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-000995-24 Sponsor Protocol Number: GWEP1332 Start Date*: 2014-09-09
    Sponsor Name:GW Research Ltd
    Full Title: A double-blind, placebo-controlled two-part study to investigate the dose-ranging safety and pharmacokinetics, followed by the efficacy and safety of cannabidiol (GWP42003-P) in children and young ...
    Medical condition: Dravet Syndrome
    Disease: Version SOC Term Classification Code Term Level
    18.0 10010331 - Congenital, familial and genetic disorders 10073677 Severe myoclonic epilepsy of infancy PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-000936-17 Sponsor Protocol Number: GWEP1560 Start Date*: 2019-07-23
    Sponsor Name:GW Research Ltd
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Single-Ascending Dose Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of GWP42003-P in Conjunction with Hypothermia in Neonates with ...
    Medical condition: Neonatal Hypoxic-Ischemic Encephalopathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10070512 Hypoxic-ischemic encephalopathy LLT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10050081 Neonatal hypoxia PT
    Population Age: Preterm newborn infants, Newborns, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2021-001959-13 Sponsor Protocol Number: EPICDKL5 Start Date*: 2021-12-02
    Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
    Full Title: Adjunctive cannabidiol therapy in patients with CDKL5 deficiency disorder. Interventional drug study on efficacy and safety with focus on seizure effects
    Medical condition: patients with CDKL5
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10015039 Epilepsy congenital PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002786-35 Sponsor Protocol Number: CUA1 Start Date*: 2020-06-25
    Sponsor Name:Charlotte Uggerhøj Andersen
    Full Title: Pharmacokinetics and side effects for tetrahydrocannabinol and cannabidiol (Sativex) among patients with chronic kidney disease and patients on dialysis.
    Medical condition: Chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 15 09:06:57 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA